TGFB1 and inflammatory bowel disease: After 12 weeks, there were significant decreases in fecal calprotectin, Mayo score, ESR (p < 0.001), INF-γ (p < 0.001), IL-6 (p < 0.001), waist circumference (p = 0.02), diastolic blood pressure (DBP) (p < 0.001), and systolic blood pressure (SBP) (p < 0.001), as well as a significant increase in TGF-β (p < 0.001) and Inflammatory Bowel Disease Questionnaire-9 (IBDQ-9) score in the GF and FO groups compared to control [37].